Skip to main content
Premium Trial:

Request an Annual Quote

SpeeDx Signs Distributions Deals Across Europe

NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx announced today that it has signed four new distribution deals in order to strengthen the reach of its products into Europe.

Axonlab will now distribute the firm's diagnostics in Germany, Belgium, the Netherlands, Luxembourg, and Switzerland; Vircell will distribute the products in Spain; Diamedica will distribute SpeeDx's diagnostics in Estonia, Latvia, and Lithuania; and Biomedica will handle distribution in Central Eastern Europe.

Financial terms of the deals were not disclosed.

These agreements were timed to coordinate with the release of ResistancePlus GC, SpeeDx's new test that combines Neisseria gonorrhoeae detection with markers for ciprofloxacin susceptibility. The test complements the company's ResistancePlus MG assay that simultaneously detects Mycoplasma genitalium and genetic markers for azithromycin resistance. There are further plans to expand ResistancePlus MG tests to include markers for resistance to second-line antibiotics, SpeeDx said. The SpeeDx portfolio also includes a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum.

"We welcome our new partners and the additional support they will bring to these significant European markets," SpeeDx CEO Colin Denver said in a statement. "Demand for ResistancePlus MG has increased in response to updates in management guidelines for Mycoplasma genitalium, and we anticipate further interest with the planned expansion of our portfolio."

In April, SpeeDx signed a distribution deal for its molecular diagnostics in the UK and Ireland with Serosep.